N-Desmethyl Imatinib
Share product
- structure.search.product.name N-Desmethyl Imatinib
- Product Code: TRC-D292045
- CAS Number: 404844-02-6
- Brand: TRC
Product Overview
Product Code
TRC-D292045
CAS Number
EP Description
Imatinib EP Impurity C
Product Format
Neat
Molecular Formula
C28 H29 N7 O
Molecular Weight
479.58
Product Categories
TRC, Impurity Reference Materials , Enzyme inhibitors, Kinase Modulators, Kinase Inhibitors, Cancer Research Chemicals and Analytical Standards
Purity
>95% (HPLC)
Documentation
Looking for another lot?
To view all certificates of analysis immediately, please login to your account
or
Email download link
{{ errors.first('RequestCoaForm.lotNumber') }}
{{ errors.first('RequestCoaForm.requestEmail') }}
For information about our data processing activities, please visit our Privacy Notice.
Enter your email address and we'll email you the relevant CoA for lots:
{{ coaPopupData.packSize.coaSelectedLotNumbers }}
{{ errors.first('SendDownloadCoaLinkForm.coaEmail') }}
We will be sending the CoA to your email address {{ coaEmailPopupData.userEmail }}
Your request has been sent to our sales team to process.
Product Information
Chemical Data
Analyte Name
N-Desmethyl Imatinib
CAS Number
404844-02-6
Molecular Formula
C28 H29 N7 O
Molecular Weight
479.58
Accurate Mass
479.2434
SMILES
Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc4nccc(n4)c5cccnc5
InChI
InChI=1S/C28H29N7O/c1-20-4-9-24(17-26(20)34-28-31-12-10-25(33-28)23-3-2-11-30-18-23)32-27(36)22-7-5-21(6-8-22)19-35-15-13-29-14-16-35/h2-12,17-18,29H,13-16,19H2,1H3,(H,32,36)(H,31,33,34)
IUPAC
N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(piperazin-1-ylmethyl)benzamide
Product Data
Storage Temperature
-20°C
Shipping Temperature
Room Temperature
Country of Origin
CANADA
Product Type
Metabolite; Impurity
Product Format
Neat
API Family
Purity
>95% (HPLC)
Product Description
N-Desmethyl Imatinib (Imatinib EP Impurity C) is a metabolite of Gleevec, a tyrosine kinase inhibitor which is highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). It is a COVID19-related research product.
References: Schindler, T., et al.: Science, 289, 1938 (2000), Drucker, B.J., et al.: N. Engl. J. Med., 344, 1031 (2001),